STIM— Neuronetics, Inc.

Health Care$151M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
Total Revenues	$149.2M+99.2%	$74.9M+5.0%	$71.3M+9.4%	$65.2M
Total Cost of revenues	$76.8M+270.7%	$20.7M+5.5%	$19.6M+26.9%	$15.5M
Gross profit	$72.3M+33.5%	$54.2M+4.8%	$51.7M+4.0%	$49.7M
Sales and marketing	$47.5M+4.0%	$45.6M-3.6%	$47.3M-5.3%	$50.0M
General and administrative	$49.7M+63.9%	$30.3M+19.3%	$25.4M-0.4%	$25.5M
Research and development	$6.6M-48.4%	$12.8M+34.2%	$9.5M+1.9%	$9.3M
Total operating expenses	$103.7M+16.9%	$88.7M+7.9%	$82.3M-3.0%	$84.8M
Loss from operations	-$31.4M+9.0%	-$34.6M-13.1%	-$30.6M+13.0%	-$35.1M
Interest expense	$8.4M+15.5%	$7.3M+34.3%	$5.4M+27.6%	$4.3M
Loss on extinguishment of debt	$4.4M	—	—	—
Other income, net	-$716K+71.9%	-$2.5M+56.0%	-$5.8M-162.8%	-$2.2M
Net loss	-$39.1M+10.5%	-$43.7M-44.8%	-$30.2M+18.8%	-$37.2M
Less: Net loss attributable to non-controlling interest	-$137K-621.1%	-$19K	—	—
Net loss attributable to Neuronetics stockholders'	-$39.0M+10.8%	-$43.7M-44.8%	-$30.2M+18.8%	-$37.2M
Net loss per share of common stock outstanding, basic attributable to Neuronetics stockholders'	-$590.00+57.2%	-$1380.00-31.4%	-$1050.00+23.9%	-$1380.00
Net loss per share of common stock outstanding, diluted attributable to Neuronetics stockholders'	-$590.00+57.2%	-$1380.00-31.4%	-$1050.00+23.9%	-$1380.00
Weighted average common shares outstanding, basic (in shares)	66.0M+107.8%	31.7M+10.7%	28.7M+6.5%	26.9M
Weighted average common shares outstanding, diluted (in shares)	66.0M+107.8%	31.7M+10.7%	28.7M+6.5%	26.9M
Products and Other
Services

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Upgrade to Pro →

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.